BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

RNL Bio and stART Licensing, Inc. Settled Patent Disputes and Concluded a License Agreement


1/12/2010 8:33:40 AM

SEOUL, South Korea, Jan. 11 /PRNewswire/ -- RNL Bio Co., Ltd. (Representative Director Jung Chan Ra, www.rnl.co.kr), a Korean company that has pioneered the commercialization of dog-cloning services, and Start Licensing, Inc. of the United States have agreed to dismiss their litigation and have concluded a license agreement as of January 11, 2010. Start Licensing, which started its history in 2005 as the joint venture between Geron Corporation and Exeter Life Sciences, was merged with ViaGen, Inc., the leading global livestock cloning and genomics company, in 2008. Start Licensing manages and licenses a broad portfolio of intellectual property rights related to animal reproductive technologies, including the technology developed and owned by Roslin Institute (Edinburgh) for the cloning of Dolly the sheep (collectively, "Dolly Patents").

According to Mr. Baek-Kyu Lee of Kim & Chang, a law firm representing Start Licensing, and Mr. Young-Mo Kwon of Lee & Ko, a law firm representing RNL Bio, the settlement has changed the relationship between Start Licensing and RNL Bio from that of competitors to global business partners.

Mr. Jung Chan Ra, President of RNL Bio, stated that with the settlement with Start Licensing, the patent dispute, which had been the sole remaining obstacle in the company's efforts to expand dog cloning services to the global market has been completely resolved, and as the world's sole dog-cloning services provider, RNL Bio will expand its services overseas, starting with countries that have the greatest demands such as the United States, Japan, China and Russia. Mr. Ra also stated that RNL Bio plans to expand its business to cloning of detection dogs, theme park for cloned dogs, and development of improved breeds via transgenic cloning technologies.

About Start Licensing

About RNL Bio

CONTACT: RNL Bio, Press Center, (02) 874-0686, ext. 108

Web site: http://www.rnl.co.kr/



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES